Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
12.40
+0.38 (3.16%)
At close: May 16, 2025, 4:00 PM
12.33
-0.07 (-0.56%)
After-hours: May 16, 2025, 4:02 PM EDT
Inhibrx Biosciences Revenue
Inhibrx Biosciences had revenue of $200.00K in the twelve months ending March 31, 2025, down -88.78% year-over-year. In the year 2024, Inhibrx Biosciences had annual revenue of $200.00K, down -88.89%.
Revenue (ttm)
$200.00K
Revenue Growth
-88.78%
P/S Ratio
892.44
Revenue / Employee
$1,242
Employees
161
Market Cap
178.49M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 200.00K | -1.60M | -88.89% |
Dec 31, 2023 | 1.80M | 485.00K | 36.88% |
Dec 31, 2022 | 1.32M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionINBX News
- 2 days ago - Inhibrx Reports First Quarter 2025 Financial Results - PRNewsWire
- 6 weeks ago - Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President - PRNewsWire
- 2 months ago - Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results - PRNewsWire
- 4 months ago - Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer - PRNewsWire
- 4 months ago - Inhibrx Biosciences Announces Loan Agreement with Oxford Finance - PRNewsWire
- 6 months ago - Inhibrx Biosciences Reports Third Quarter 2024 Financial Results - PRNewsWire
- 6 months ago - Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform - Seeking Alpha
- 6 months ago - Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation - PRNewsWire